{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:32:30Z","timestamp":1720053150502},"reference-count":55,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,14]],"date-time":"2010-11-14T00:00:00Z","timestamp":1289692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Furazolidone is a much cheaper drug with a very low resistance against <jats:italic>Helicobacter pylori<\/jats:italic> compared to clarithromycin. We aim to evaluate safety and efficacy of a sequential furazolidone\u2010based regimen versus clarithromycin\u2010based therapy in <jats:italic>H.\u00a0pylori<\/jats:italic> eradication for ulcer disease.<\/jats:p><jats:p><jats:bold>Materials:\u2002<\/jats:bold> Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB\u2010M\u2010F; metronidazole (M) (500\u2003mg bid) for the first 5\u2003days, followed by furazolidone (F) (200\u2003mg bid) for the second 5\u2003days; OAC\u2010P; clarithromycin (C) (500\u2003mg bid) for 10\u2003days; and OAB\u2010C\u2010F; clarithromycin (500\u2003mg bid) for the first 5\u2003days and furazolidone (200\u2003mg bid) for the second 5\u2003days. All groups received omeprazole (O) (20\u2003mg bid) and amoxicillin (A) (1\u2003g bid). Groups OAB\u2010M\u2010F and OAB\u2010C\u2010F were also given bismuth subcitrate (B) (240\u2003mg bid), whereas a placebo (P) was given to group OAC\u2010P. Adverse events were scored and recorded. Two months after treatment, a C<jats:sup>13<\/jats:sup>\u2010urea breath test was performed.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Three hundred and ten patients were enrolled and 92 (OAB\u2010M\u2010F), 95 (OAC\u2010P), and 98 (OAB\u2010C\u2010F) completed the study. The intention\u2010to\u2010treat eradication rates were 78.5% (95% CI\u2003=\u200369\u201385), 81.1% (95% CI\u2003=\u200373\u201388), and 82% (95% CI\u2003=\u200374\u201389), and per\u2010protocol eradication rates were 91.3% (95% CI\u2003=\u200383\u201396), 90.4% (95% CI\u2003=\u200382\u201395), and 88.7% (95% CI\u2003=\u200381\u201394), for group OAB\u2010M\u2010F, OAC\u2010P, and OAB\u2010C\u2010F, respectively. Eradication rate differences did not reach statistical significance. The most common adverse event, bad taste, occurred in all groups, but more frequently in groups OAC\u2010P (34%) and OAB\u2010C\u2010F (32%), than OAB\u2010M\u2010F (14%) (<jats:italic>p<\/jats:italic>\u2003&lt;\u2003.05). Adverse symptoms score were 0.88\u2003\u00b1\u20032.05 in group OAB\u2010M\u2010F, 1.15\u2003\u00b1\u20031.40 in group OAC\u2010P, and 1.87\u2003\u00b1\u20031.62 in group OAB\u2010C\u2010F.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Furazolidone can replace clarithromycin in <jats:italic>H.\u00a0pylori<\/jats:italic> eradication regimens because of lack of development of resistance and very low cost.<\/jats:p>","DOI":"10.1111\/j.1523-5378.2010.00798.x","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T05:08:56Z","timestamp":1289797736000},"page":"497-504","source":"Crossref","is-referenced-by-count":16,"title":["Sequential Metronidazole\u2010Furazolidone or Clarithromycin\u2010Furazolidone Compared to Clarithromycin\u2010Based Quadruple Regimens for the Eradication of <i>Helicobacter pylori<\/i> in Peptic Ulcer Disease: A Double\u2010Blind Randomized Controlled Trial"],"prefix":"10.1111","volume":"15","author":[{"given":"Saghi","family":"Riahizadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahram","family":"Agah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasrin","family":"Zendehdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasoul","family":"Sotoudehmanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naser","family":"Ebrahimi\u2010Dariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Pourshams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homayoon","family":"Vahedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javad","family":"Mikaeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morteza","family":"Khatibian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadegh","family":"Massarrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2006.00459.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.50019.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.87"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i11.1656"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i5.668"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01276.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(03)00268-8"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2000.00011.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90657-1"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.306-308.2001"},{"key":"e_1_2_5_12_2","first-page":"1048","article-title":"Double\u2010blind short\u2010term trial of furazolidone in peptic ulcer","volume":"1","author":"Zheng ZT","year":"1985","journal-title":"Lancet"},{"key":"e_1_2_5_13_2","first-page":"276","article-title":"Furazolidone in peptic ulcer","volume":"2","author":"Zhao HY","year":"1985","journal-title":"Lancet"},{"key":"e_1_2_5_14_2","first-page":"286","article-title":"Antimicrobial effectiveness of furazolidone against metronidazole","volume":"12","author":"Safaralizadeh R","year":"2006","journal-title":"East Mediterr Health J"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.860"},{"key":"e_1_2_5_16_2","first-page":"161","article-title":"Furazolidone\u2010based, metronidazole\u2010based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease","volume":"10","author":"Khatibian M","year":"2007","journal-title":"Arch Iran Med"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.6224"},{"key":"e_1_2_5_18_2","first-page":"134","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel\u2010group randomized trials","volume":"17","author":"Moher D","year":"2001","journal-title":"Ann Intern Med"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.101634"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01393.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05982.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2006.03.004"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00286-7"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01173.x"},{"key":"e_1_2_5_25_2","first-page":"525","article-title":"Prevalence of Helicobacter pylori resistance to antibiotics and its influence on the treatment outcome in China: a multicenter clinical study","volume":"12","author":"Chinese Helicobacter pylori Research Group, Chinese Society of Gastroenterology","year":"2007","journal-title":"Weichang Bingxue"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1807-59322005000600010"},{"issue":"1","key":"e_1_2_5_27_2","first-page":"S37","article-title":"My approach to Helicobacter pylori eradication","volume":"11","author":"Bazzoli F","year":"1999","journal-title":"Eur Gastroenterol Hepatol"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199907000-00004"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02737.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03531.x"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091336"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000048865"},{"key":"e_1_2_5_33_2","first-page":"105","article-title":"The efficacy of furazolidone\u2010based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole\u2010based quadruple therapy","volume":"9","author":"Ebrahimi\u2010Dariani N","year":"2003","journal-title":"Med Sci Monit"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2002.00087.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01299.x"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01223.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00709.x"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032005000200009"},{"key":"e_1_2_5_39_2","first-page":"23","article-title":"New ultrashort scheme for Helicobacter pylori infection eradication using tetracyline, furazolidone, and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia","volume":"25","author":"Araujo\u2010Castillo R","year":"2005","journal-title":"Rev Gastroenterol Peru"},{"key":"e_1_2_5_40_2","first-page":"27","article-title":"Eradication of Helicobacter pylori induodenal ulcer disease: tetracycline and furazolidone vs. metronidazole and amoxicillin in omeprazole\u2010based triple therapy","volume":"8","author":"Mansour\u2010Ghanaei F","year":"2002","journal-title":"Med Sci Monit"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01122.x"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00845.x"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00640.x"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00487.x"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00653.x"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02210.x"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02416.x"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0041-87812002000500003"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-9-38"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00931.x"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03058.x"},{"key":"e_1_2_5_52_2","first-page":"60","article-title":"Susceptibility of various strains of Helicobacter pylori to selected agents","volume":"2","author":"Siavoshi F","year":"2000","journal-title":"Arch Iran Med"},{"key":"e_1_2_5_53_2","first-page":"177","article-title":"Increase in resistance rates of H.\u00a0pylori isolates to metronidazole and tetracycline\u2010comparison of three 3\u2010year studies","volume":"13","author":"Siavoshi F","year":"2010","journal-title":"Arch Iran Med"},{"key":"e_1_2_5_54_2","first-page":"1","article-title":"Treatment of Helicobacter pylori infection in Iran: low efficacy of recommended western regimens","volume":"7","author":"Malekzadeh R","year":"2004","journal-title":"Arch Iran Med"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910480420"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500216"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1523-5378.2010.00798.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1523-5378.2010.00798.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T11:19:38Z","timestamp":1698664778000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1523-5378.2010.00798.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,14]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1523-5378.2010.00798.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-5378.2010.00798.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,14]]}}}